IRF4 is a novel mediator for neuronal survival in ischaemic stroke

Cell Death and Differentiation

Volumn 21, Issue 6, 2014, Pages 888-903

  Guo, S ^a,b   Li, Z Z ^c   Jiang, D S ^a,b   Lu, Y Y ^a,b   Liu, Y ^b   Gao, L ^d   Zhang, S M ^a,b   Lei, H ^e   Zhu, L H ^a,b   Zhang, X D ^b   Liu, D P ^c   Li, H ^a,b  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

^c PEKING UNION MEDICAL COLLEGE   (China)

^d Union Hospital   (China)

^e INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

IRF4; ischaemic stroke; neuronal survival; SRF

Indexed keywords

GLUCOSE; INTERFERON REGULATORY FACTOR 4; OXYGEN; SERUM RESPONSE FACTOR; TRANSCRIPTION FACTOR; INTERFERON REGULATORY FACTOR; INTERFERON REGULATORY FACTOR-4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CELL SURVIVAL; CONTROLLED STUDY; GENE; GENETIC TRANSCRIPTION; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; MOUSE; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FAMILY; SIGNAL TRANSDUCTION; SRF GENE; TRANSGENIC MOUSE; UPREGULATION; ANIMAL; APOPTOSIS; CEREBROVASCULAR ACCIDENT; GENETICS; HUMAN; METABOLISM; NERVE CELL; PATHOLOGY; REPERFUSION INJURY;

MUS;

ANIMALS; APOPTOSIS; CELL SURVIVAL; HUMANS; INTERFERON REGULATORY FACTORS; MICE; MICE, KNOCKOUT; NEURONS; REPERFUSION INJURY; SIGNAL TRANSDUCTION; STROKE;

EID: 84899928972     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2014.9     Document Type: Article

References (39)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013; 127: e6-6e245.
2. Rothwell PM, Algra A, Amarenco P. Medical treatment in acute and long-term secondary prevention after transient ischaemic attack and ischaemic stroke. Lancet 2011; 377: 1681-1692.
3. Langhorne P, Bernhardt J, Kwakkel G. Stroke rehabilitation. Lancet 2011; 377: 1693-1702.
4. Rha JH, Saver JL. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke 2007; 38: 967-973.
5. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1, 026 experimental treatments in acute stroke. Ann Neurol 2006; 59: 467-477.
6. Iadecola C, Anrather J. Stroke research at a crossroad: asking the brain for directions. Nat Neurosci 2011; 14: 1363-1368.
7. Chang SH, Poser S, Xia Z. A novel role for serum response factor in neuronal survival. J Neurosci 2004; 24: 2277-2285.
8. Tamura T, Yanai H, Savitsky D, Taniguchi T. The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol 2008; 26: 535-584.
9. Lu J, Bian ZY, Zhang R, Zhang Y, Liu C, Yan L et al. Interferon regulatory factor 3 is a negative regulator of pathological cardiac hypertrophy. Basic Res Cardiol 2013; 108: 326.
10. Eisenbeis CF, Singh H, U Storb. Pip, a novel IRF family member, is a lymphoid-specific, PU.1-dependent transcriptional activator. Genes Dev 1995; 9: 1377-1387.
11. Wang XA, Zhang R, Jiang D, Deng W, Zhang S, Deng S et al. Interferon regulatory factor 9 protects against hepatic insulin resistance and steatosis in male mice. Hepatology 2013; 58: 603-616.
12. Jiang DS, Luo YX, Zhang R, Zhang XD, Chen HZ, Zhang Y et al. Interferon regulatory factor 9 protects against cardiac hypertrophy by targeting myocardin. Hypertension 2014; 63: 119-127.
13. Jiang DS, Bian ZY, Zhang Y, Zhang SM, Liu Y, Zhang R et al. Role of interferon regulatory factor 4 in the regulation of pathological cardiac hypertrophy. Hypertension 2013; 61: 1193-1202.
14. Gualco G, Weiss LM, Bacchi CE. MUM1/IRF4: a review. Appl Immunohistochem Mol Morphol 2010; 18: 301-310.
15. Shaffer AL, Emre NC, Romesser PB, Staudt LM. IRF4: immunity. malignancy! therapy. Clin Cancer Res 2009; 15: 2954-2961.
16. Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao W et al. IRF4 addiction in multiple myeloma. Nature 2008; 454: 226-231.
17. Engel O, Kolodziej S, Dirnagl U, Prinz V. Modeling stroke in mice-middle cerebral artery occlusion with the filament model. J Vis Exp 2011; 47: 2423.
18. Tymianski M. Emerging mechanisms of disrupted cellular signaling in brain ischemia. Nat Neurosci 2011; 14: 1369-1373.
19. Schabitz WR, Sommer C, Zoder W, Kiessling M, Schwaninger M, Schwab S. Intravenous brain-derived neurotrophic factor reduces infarct size and counterregulates Bax and Bcl-2 expression after temporary focal cerebral ischemia. Stroke 2000; 31: 2212-2217.
20. Treisman R. Journey to the surface of the cell: Fos regulation and the SRE. EMBO J 1995; 14: 4905-4913.
21. Ramanan N, Shen Y, Sarsfield S, Lemberger T, Schütz G, Linden DJ et al. SRF mediates activity-induced gene expression and synaptic plasticity but not neuronal viability. Nat Neurosci 2005; 8: 759-767.
22. McGahan L, Hakim AM, Nakabeppu Y, Robertson GS. Ischemia-induced CA1 neuronal death is preceded by elevated FosB and Jun expression and reduced NGFI-A and JunB levels. Brain Res Mol Brain Res 1998; 56: 146-161.
23. Norman C, Runswick M, Pollock R, Treisman R. Isolation and properties of cDNA clones encoding SRF, a transcription factor that binds to the c-fos serum response element. Cell 1988; 55: 989-1003.
24. Xu WD, Pan HF, Ye DQ, Xu Y. Targeting IRF4 in autoimmune diseases. Autoimmun Rev 2012; 11: 918-924.
25. Eguchi J, Wang X, Yu S, Kershaw EE, Chiu PC, Dushay J et al. Transcriptional control of adipose lipid handling by IRF4. Cell Metab 2011; 13: 249-259.
26. Grumont RJ, Gerondakis S. Rel induces interferon regulatory factor 4 (IRF-4) expression in lymphocytes: modulation of interferon-regulated gene expression by rel/nuclear factor kappaB. J Exp Med 2000; 191: 1281-1292.
27. Schneider A, Martin-Villalba A, Weih F, Vogel J, Wirth T, Schwaninger M. NF-kappaB is activated and promotes cell death in focal cerebral ischemia. Nat Med 1999; 5: 554-559.
28. Gupta S, Jiang M, Anthony A, Pernis AB. Lineage-specific modulation of interleukin 4 signaling by interferon regulatory factor 4. J Exp Med 1999; 190: 1837-1848.
29. Sciammas R, Shaffer AL, Schatz JH, Zhao H, Staudt LM, Singh H. Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. Immunity 2006; 25: 225-236.
30. Marecki S, Fenton MJ. The role of IRF-4 in transcriptional regulation. J Interferon Cytokine Res 2002; 22: 121-133.
31. Gobin SJ, Biesta P, Van den Elsen PJ. Regulation of human beta 2-microglobulin transactivation in hematopoietic cells. Blood 2003; 101: 3058-3064.
32. Rengarajan J, Mowen KA, McBride KD, Smith ED, Singh H, Glimcher LH. Interferon regulatory factor 4 (IRF4) interacts with NFATc2 to modulate interleukin 4 gene expression. J Exp Med 2002; 195: 1003-1012.
33. Rieker C, Schober A, Bilbao A, Schutz G, Parkitna JR. Ablation of serum response factor in dopaminergic neurons exacerbates susceptibility towards MPTP-induced oxidative stress. Eur J Neurosci 2012; 35: 735-741.
34. Wang L, Lu Y, Deng S, Zhang Y, Yang L, Guan Y et al. SHPS-1 deficiency induces robust neuroprotection against experimental stroke by attenuating oxidative stress. J Neurochem 2012; 122: 834-843.
35. Wang L, Lu Y, Zhang X, Zhang Y, Jiang D, Dong X et al. Mindin is a critical mediator of ischemic brain injury in an experimental stroke model. Exp Neurol 2013; 247: 506-516.
36. Wang L, Lu Y, Guan H, Jiang D, Guan Y, Zhang X et al. Tumor necrosis factor receptor-associated factor 5 is an essential mediator of ischemic brain infarction. J Neurochem 2013; 126: 400-414.
37. Wang L, Deng S, Lu Y, Zhang Y, Yang L, Guan Y et al. Increased inflammation and brain injury after transient focal cerebral ischemia in activating transcription factor 3 knockout mice. Neuroscience 2012; 220: 100-108.
38. Lu YY, Li ZZ, Jiang DS, Wang L, Zhang Y, Chen K et al. TRAF1 is a critical regulator of cerebral ischaemia-reperfusion injury and neuronal death. Nat Commun 2013; 4: 2852.
39. Xia CF, Smith Jr RS, Shen B, Yang ZR, Borlongan CV, Chao L et al. Postischemic brain injury is exacerbated in mice lacking the kinin B2 receptor. Hypertension 2006; 47: 752-761.